AMGN:NASDAQ
Amgen Inc
$382.47
arrow_downward
-2.25%(-8.80) 1D
$383.00
arrow_upward
+0.14% (+0.53)bedtimeAfter hours
Closed: Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN...
Open
$387.84
High
$391.67
Low
$381.51
Mkt. cap
206.78B
Avg. vol.
2.66M
Volume
0.00
Dividend
2.64%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
23.75
52-wk high
$447.01
52-wk low
$269.77
EPS
$16.10
Beta
0.43
Shares outstanding
540.63M
No. of employees
32K
Open
$387.84
High
$391.67
Low
$381.51
Mkt. cap
206.78B
Avg. vol.
2.66M
Volume
0.00
Dividend
2.64%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
23.75
52-wk high
$447.01
52-wk low
$269.77
EPS
$16.10
Beta
0.43
Shares outstanding
540.63M
No. of employees
32K
News stories
From web sources and news partners
Zacks
·
6 hours ago
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
Yahoo Finance
·
6 hours ago
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
The Globe and Mail
·
11 hours ago
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
The Motley Fool
·
11 hours ago
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
FoundedApr 8, 1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com